RiverVest Venture Partners focuses exclusively on innovations in life sciences, a field in which their team has significant research, clinical, operational and investment expertise. The team's deep domain experience allows them to identify promising investment opportunities, particularly in biopharmaceuticals and medical devices. They provide practical advice and strategic leadership to help entrepreneurs drive early-stage companies forward. RiverVest founds and actively incubates life science companies, including through its Archer Seed Fund. The Firm also invests in select later-stage opportunities to diversify risk and maximize portfolio returns. In every case, it takes a hands-on investment approach, preferring to be represented on the boards of their portfolio companies.
A biopharmaceutical company focused on developing treatments for inner and middle ear diseases
Amplyx Pharmaceuticals, Inc. is a preclinical stage company focusing on the development of small molecule drugs.
Scout Bio is a biotechnology company that focuses on transforming pet medicine by providing a pipeline of therapeutics for chronic pet health conditions.
Now Avalyn Pharma, a biopharmaceutical company developing therapies to treat idiopathic pulmonary fibrosis and other respiratory diseases
OncoResponse is a company providing cancer research into immunotherapies and the newest technologies for oncologists.
A company that develops therapeutic antibodies to treat diseases and allergies
Mirum Pharmaceuticals is a Menlo Park, California-based company.
InterVene is a South San Francisco, California-based company.
Arch Oncology is a Brisbane, California-based company.